A Phase 4 interventional study of crizotinib in NSCLC, ALCL and IMT, sponsored by Pfizer. Active, not recruiting at 13 sites in 5 countries. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 4, and was the 22nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Hunan Province Tumor Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 0 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 23 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 109th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2021, is one of 4 in phase 4, reaches primary completion later than 12 of the 25 other live ones, and was the 119th registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
2 of the studies testing crizotinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Participants not previously enrolled or who have discontinued study treatment or safety follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for participation in this continuation study.
Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:
Pediatric Participants (\<18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded:
crizotinib oral treatment
Drug: crizotinib
crizotinib oral treatment
Also known as: XALKORI
Number of participants with adverse events leading to permanent discontinuation of study intervention
Safety data collection in this study will permit further characterization of the safety profile of crizotinib.
Time frame: Baseline up to approximately 5 years
Number of serious adverse events reported for all participants
Safety data collection in this study will permit further characterization of the safety profile of crizotinib.
Time frame: Baseline up to approximately 5 years
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Started Dec 2021 (actual). Primary completion is estimated for Mar 2028, 74 months after the start.
Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 74 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib
Carcinoma, Non-Small-Cell Lung →